Clotles Plus (aspirin + clopidogrel bisulphate): Uses, Dosage & Side Effects

What it's for (Indications)

This combination medication, comprising aspirin and clopidogrel bisulphate, is indicated for the prevention of atherothrombotic events in adult patients presenting with acute coronary syndrome (ACS).
This includes patients with unstable angina or non-ST-segment elevation myocardial infarction (NSTEMI), whether medically managed or undergoing percutaneous coronary intervention (PCI), and patients with ST-segment elevation myocardial infarction (STEMI) receiving thrombolytic therapy or undergoing primary PCI.
Furthermore, it is prescribed for patients with a history of myocardial infarction, ischemic stroke, or established peripheral arterial disease, particularly after recent revascularization procedures such as coronary stenting, to reduce the risk of subsequent thrombotic events like recurrent myocardial infarction, ischemic stroke, and cardiovascular death.
The specific duration of dual antiplatelet therapy (DAPT) should be determined by the treating physician based on the patient's individual clinical profile, type of revascularization, and associated risk factors for both thrombotic and bleeding events, adhering to current clinical guidelines.

Dosage Information

Type	Guideline
Standard	The dosage regimen for the aspirin and clopidogrel combination must be individualized based on the specific clinical indication, patient characteristics, and local prescribing guidelines, as typically available in fixed-dose combinations (e.g., Norplate-S). For instance, in acute coronary syndromes, a loading dose of clopidogrel (e.g., 300 mg or 600 mg) is often administered, followed by a maintenance dose of 75 mg daily. Aspirin is commonly prescribed at a low dose, such as 75 mg or 81 mg daily, though an initial loading dose (e.g., 160 mg to 325 mg) may also be given in acute settings. Following revascularization procedures like stent implantation, dual antiplatelet therapy is typically continued for a specific duration, ranging from 1 to 12 months or longer, depending on the type of stent, clinical presentation, and individual risk-benefit assessment. It is crucial to strictly adhere to the prescribed dose and duration and to consult a healthcare professional before making any changes, discontinuing the medication, or for specific dosage adjustments in special populations such as those with renal or hepatic impairment.

Type

Guideline

Standard

The dosage regimen for the aspirin and clopidogrel combination must be individualized based on the specific clinical indication, patient characteristics, and local prescribing guidelines, as typically available in fixed-dose combinations (e.g., Norplate-S). For instance, in acute coronary syndromes, a loading dose of clopidogrel (e.g., 300 mg or 600 mg) is often administered, followed by a maintenance dose of 75 mg daily. Aspirin is commonly prescribed at a low dose, such as 75 mg or 81 mg daily, though an initial loading dose (e.g., 160 mg to 325 mg) may also be given in acute settings. Following revascularization procedures like stent implantation, dual antiplatelet therapy is typically continued for a specific duration, ranging from 1 to 12 months or longer, depending on the type of stent, clinical presentation, and individual risk-benefit assessment. It is crucial to strictly adhere to the prescribed dose and duration and to consult a healthcare professional before making any changes, discontinuing the medication, or for specific dosage adjustments in special populations such as those with renal or hepatic impairment.

Safety & Warnings

Common Side Effects

The use of aspirin and clopidogrel combination therapy carries a risk of various side effects, predominantly related to its antiplatelet activity.
The most common adverse effects include increased bleeding, which can manifest as epistaxis (nosebleeds), bruising, hematoma formation, or gastrointestinal bleeding (e.
g.
, dyspepsia, abdominal pain, nausea, diarrhea, and potentially more serious events like peptic ulcers or hemorrhage).
Other less common but potentially serious side effects associated with clopidogrel include thrombotic thrombocytopenic purpura (TTP), a rare but life-threatening condition characterized by thrombocytopenia and microangiopathic hemolytic anemia, typically occurring within the first two weeks of treatment.
Aspirin can induce hypersensitivity reactions, including bronchospasm, angioedema, or urticaria, particularly in individuals with aspirin-exacerbated respiratory disease.
Other reported side effects include rash, pruritus, headache, dizziness, and alterations in liver function tests.
Patients should be advised to report any signs of unusual bleeding or severe adverse reactions to their healthcare provider immediately.

Serious Warnings

Black Box Warning: Clopidogrel, a component of this medication, is a prodrug that requires metabolic activation by cytochrome P450 (CYP2C19) to form its active metabolite. Treatment with clopidogrel at recommended doses may result in lower exposure to the active metabolite and reduced antiplatelet activity in patients who are poor metabolizers of CYP2C19. These patients may remain at higher risk for cardiovascular events following a myocardial infarction or stent placement. Tests are available to identify patients who are CYP2C19 poor metabolizers. Consider alternative treatment strategies or adjust clopidogrel dosing in patients identified as CYP2C19 poor metabolizers, in consultation with a healthcare professional, based on the clinical context and risk assessment. The reduced antiplatelet effect in poor metabolizers can lead to treatment failure, including stent thrombosis and other serious cardiovascular events.
Patients receiving aspirin and clopidogrel combination therapy must be closely monitored for an increased risk of bleeding.
This risk is amplified in patients with a history of gastrointestinal bleeding or peptic ulcer disease, those undergoing surgical procedures (including dental), or those concurrently taking other medications that affect hemostasis, such as anticoagulants (e.
g.
, warfarin, direct oral anticoagulants), nonsteroidal anti-inflammatory drugs (NSAIDs), or selective serotonin reuptake inhibitors (SSRIs).
It is generally recommended to discontinue this medication for a specified period (e.
g.
, 5-7 days for clopidogrel, 7-10 days for aspirin) before elective surgery, though this decision should be made in consultation with the treating physician.
Patients should be educated about the signs and symptoms of bleeding and advised to seek immediate medical attention if they occur.
Furthermore, clopidogrel's efficacy can be reduced in individuals who are poor metabolizers of CYP2C19, potentially leading to an increased risk of cardiovascular events.
Aspirin is contraindicated in children and adolescents with viral infections due to the risk of Reye's syndrome.
Caution is also advised in patients with severe hepatic or renal impairment.

How it Works (Mechanism of Action)

Aspirin and clopidogrel bisulphate exert their therapeutic effects through distinct yet complementary mechanisms of antiplatelet action, providing a synergistic inhibition of platelet aggregation. Aspirin, a non-steroidal anti-inflammatory drug (NSAID), functions by irreversibly inhibiting cyclooxygenase-1 (COX-1) and, to a lesser extent, COX-2 enzymes. This inhibition specifically reduces the production of thromboxane A2 (TxA2) within platelets. TxA2 is a potent vasoconstrictor and aggregator of platelets; thus, by preventing its synthesis, aspirin effectively inhibits platelet activation for the lifespan of the platelet (approximately 7-10 days). Clopidogrel, on the other hand, is a prodrug that requires metabolic activation, primarily by the cytochrome P450 isoenzyme CYP2C19 in the liver, into an active thiol metabolite. This active metabolite irreversibly binds to the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. By blocking the P2Y12 receptor, clopidogrel prevents ADP-mediated activation of the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor complex, which is crucial for fibrinogen binding and platelet cross-linking. This inhibition also lasts for the lifespan of the platelet, making the combination highly effective in preventing thrombotic events.